Allarity Therapeutics To Receive European Patent For DRP Companion Diagnostic For Stenoparib; Patent Pending In US, Japan, China, Australia, And India
Portfolio Pulse from Benzinga Newsdesk
Allarity Therapeutics is set to receive a European patent for its DRP companion diagnostic for Stenoparib. The patent is also pending in the US, Japan, China, Australia, and India.
October 22, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Allarity Therapeutics is receiving a European patent for its DRP companion diagnostic for Stenoparib, with pending applications in several major markets.
The European patent grant is a significant milestone for Allarity Therapeutics, potentially enhancing its market position and credibility. The pending patents in other major markets like the US and China could further expand its reach and impact positively on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90